91̽»¨

Research summary

We are studying the role of the MYB oncogene in acute leukemias in children and adults. MYB is a master transcription factor that regulates cell cycle progression, differentiation, apoptosis, and chromatin condensation. It is overexpressed in the majority of human leukemias.

We have recently identified several new small molecule MYB inhibitors that cause growth arrest, differentiation, and cell death in leukemia cells. We have also shown that MYB expression is a potential biomarker for relapse in childhood acute lymphoblastic leukemia. We are currently developing new MYB-targeted therapy and further investigating the biological and clinical relevance of MYB in acute leukemias.

Research tools and resources

We use a wide range of cell and molecular biological assays and bioinformatics to study MYB function in cultured leukemic cells. We are validating our findings in primary patient material and in mouse models. The group works together with international and national collaboration partners.

Current group members

Mattias Andersson, Associate professor
Peter Larsson, Postdoc
Elisabeth Vidblom, Master student
 

Selected publications

1. MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature.
   Huang J, Fehr A, Jäwert F, Nilsson JA, Morris LGT, Stenman G, Andersson MK. Oral Oncol. 2024;151:106763. doi: 10.1016/j.oraloncology.2024.106763.
    
2. 
   Fehr A, Arvidsson G, Nordlund J, Lönnerholm G, Stenman G, Andersson MK. Genes Chromosomes Cancer. 2023. doi: 10.1002/gcc.23151.
    
3. 
   Tejera Nevado P, TeÅ¡an Tomić T, Atefyekta A, Fehr A, Stenman G, Andersson MK. Front Oncol. 2023;13:1126354. doi: 10.3389/fonc.2023.1126354.
    
4. 
   Andersson MK, Afshari MK, Andrén Y, Wick MJ, Stenman G. J Natl Cancer Inst. 2017;109:djx017. doi: 10.1093/jnci/djx017.
    
5. 
   Andersson MK*, Mangiapane G*, Nevado PT, Tsakaneli A, Carlsson T, Corda G, Nieddu V, Abrahamian C, Chayka O, Rai L, Wick M, Kedaigle A, Stenman G, Sala A. Oncogenesis. 2020;9:5. doi: 10.1038/s41389-020-0194-3. *equal contribution
    
6. 
   Persson M*, Andersson MK*, Mitani Y, Brandwein-Weber MS, Frierson HF Jr, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G. Cancers (Basel). 2022;14:3691. doi: 10.3390/cancers14153691. *equal contribution
    
7. 
   Yusenko MV, Biyanee A, Frank D, Köhler LHF, Andersson MK, Khandanpour C, Schobert R, Stenman G, Biersack B, Klempnauer KH. Cancers (Basel). 2021;14:43. doi: 10.3390/cancers14010043.
    
8. 
   Yusenko MV, Biyanee A, Andersson MK, Radetzki S, von Kries JP, Stenman G, Klempnauer KH. Cancer Lett. 2021;520:132-142. doi: 10.1016/j.canlet.2021.07.010.
    
9. 
   Yusenko MV, Trentmann A, Andersson MK, Ghani LA, Jakobs A, Arteaga Paz MF, Mikesch JH, Peter von Kries J, Stenman G, Klempnauer KH. Cancer Lett. 2020;479:61-70. doi: 10.1016/j.canlet.2020.01.039.
10. 
    SkarsgÃ¥rd LS, Andersson MK, Persson M, Larsen AC, Coupland SE, Stenman G, Heegaard S. BMJ Open Ophthalmol. 2019;4:e000362. doi: 10.1136/bmjophth-2019-00036